Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Liabilities and Shareholders Equity (2016 - 2025)

Vanda Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $488.9 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 25.49% year-over-year to $488.9 million; the TTM value through Dec 2025 reached $2.3 billion, down 9.93%, while the annual FY2025 figure was $488.9 million, 25.49% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $488.9 million at Vanda Pharmaceuticals, down from $601.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $656.2 million in Q4 2024 and bottomed at $488.9 million in Q4 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $628.3 million (2025), against an average of $614.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity rose 12.38% in 2021 before it dropped 25.49% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $593.8 million in 2021, then grew by 6.81% to $634.2 million in 2022, then rose by 2.24% to $648.4 million in 2023, then increased by 1.2% to $656.2 million in 2024, then decreased by 25.49% to $488.9 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Liabilities and Shareholders Equity are $488.9 million (Q4 2025), $601.1 million (Q3 2025), and $624.7 million (Q2 2025).